摘要
目的通过Meta分析探讨甲状腺癌组织中黏蛋白1(MUC1)表达的临床意义及其与各临床病理参数的相关性。方法检索维普、万方、中国知网、中国生物医学文献、PubMed、Web of Science、Embase、Cochrane中英文数据库中关于MUC1在甲状腺癌中表达及其意义的文献,以比值比(OR)和95%置信区间(95%CI)为效应指标,采用STATA 14软件进行Meta分析,并对发表偏倚及敏感性进行检验。结果共纳入13项病例对照研究,甲状腺癌病例组共1157例,非甲状腺癌对照组共509例。结果显示,甲状腺癌病例组MUC1表达明显高于非甲状腺癌对照组(OR=9.78,95%CI:7.49~12.78,P<0.001);伴有淋巴结转移的甲状腺癌组织中MUC1表达高于无淋巴结转移的甲状腺癌组织(OR=3.08,95%CI:1.37~6.92,P<0.05);TNM分期为Ⅲ~Ⅳ期的甲状腺癌组织中MUC1表达高于TNM分期为Ⅰ~Ⅱ期的甲状腺癌组织(OR=1.88,95%CI:1.22~2.90,P<0.05)。结论与非甲状腺癌对照组比较,甲状腺癌病例组MUC1呈高表达,且MUC1高表达与淋巴结转移、TNM分期密切相关。MUC1与甲状腺癌的发生和发展存在相关性,有望成为甲状腺癌分子研究领域的一项新靶标。
Objective The aim of this study was to investigate the clinical significance of mucin 1(MUC1)expression in thyroid carcinoma and its correlation with clinicopathological parameters through Meta-analysis.Methods The Chinese and English databases of VIP,Wanfang,CNKI,CBM,PubMed,Web of Science,Embase,Cochrane were searched for studies on the expression of MUC1 in thyroid cancer and its significance.Odds ratio(OR)and 95%confidence interval(95%CI)were used as effect indicators.STATA 14 software was used to perform the Meta-analysis,and the publication bias and sensitivity were tested.Results A total of 13 case-control studies were included,including 1157 cases with thyroid cancer and 509 controls without thyroid cancer.The results showed that MUC1 expression in thyroid cancer group was significantly higher than that in non-thyroid cancer control group(OR=9.78,95%CI:7.49-12.78,P<0.001).The expression of MUC1 in thyroid carcinoma tissues with lymph node metastasis was higher than that in thyroid carcinoma tissues without lymph node metastasis(OR=3.08,95%CI:1.37-6.92,P<0.05).The expression of MUC1 in TNM stage Ⅲ-Ⅳ thyroid cancer tissues was higher than that in TNM stage Ⅰ-Ⅱ thyroid cancer tissues(OR=1.88,95%CI:1.22-2.90,P<0.05).Conclusion Compared with the non-thyroid cancer control group,the expression of MUC1 in the thyroid cancer group was higher,and the high expression of MUC1 was closely related to lymph node metastasis and TNM stage.MUC1 is associated with the occurrence and development of thyroid cancer,and is expected to become a new target in the field of thyroid cancer molecular research.
作者
罗锦
李岚
张睿
马健波
方静怡
朱正鹏
LUO Jin;LI Lan;ZHANG Rui;MA Jianbo;FANG Jingyi;ZHU Zhengpeng(Department of Pathology,Sinopharm Dongfeng General Hospital,Hubei University of Medicine,Shiyan,Hubei 442008,China)
出处
《检验医学与临床》
CAS
2024年第22期3331-3336,3341,共7页
Laboratory Medicine and Clinic
基金
湖北省卫生健康委员会卫生健康科研项目(WJ2021F053)
湖北省十堰市科学技术研究与开发项目(2021K70)
国药东风总医院2022年度卓越计划(院内项目)青年人才项目(2022Q23)。
